ISCBH Bone School 2027
ISCBH HOME
Les Pensières Center for Global Health, Veyrier-du-Lac, Annecy, France, the venue for ICCBH Bone School 2023 on 29-31 May 2023

ISCBH Bone School 2027

Tuesday 25 May to Friday 28 May 2027

at Les Pensières Center for Global Health, Veyrier-du-Lac, Annecy, France

Welcome

The ISCBH Bone School in 2027 has been extended to a 4-day residential international educational course giving the opportunity for participants to learn about and discuss mechanisms, clinical diagnosis and treatment of paediatric bone health and rare bone diseases.

The first school took place in Dublin, Ireland in June 2022. The second and third were held in Annecy, France in May 2023 and May 2025.

Due to there being limited places for the School, there is an application process to complete for those who are interested. You can find and complete the application form by clicking on the orange button.

These are reviewed by the Co-Chairs prior to successful applicants being offered a place.  You will then be sent additional instructions about how to select your registration and accommodation and complete the payment online to secure your place at the 2027 ISCBH Bone School. 

The applications window will be open from July to October and then notifications to successful applicants will be sent out at the end of November 2026.

Aims and Objectives

On completion of this educational course participants will:

  • Understand the pathophysiological mechanisms underlying bone fragility and mineralization disorders
  • Understand how rare bone and muscle disorders affect the skeleton and growth
  • Understand bone ultrastructure and bone imaging and how chronic diseases affect bone muscle and bone
  • Be able to differentiate between mineralization and fragility disorders
  • Understand the diagnostic and therapeutic options for the management of paediatric bone disorders

Course Organisers: Wolfgang Högler (Linz, Austria) & Ciara McDonnell (Dublin, Ireland)

APPLICATIONS OPEN
REGISTRATION FEES

Who should attend?

The school has been designed for clinicians, translational researchers, senior nurse specialists and advanced allied health professionals with an interest in enhancing their depth of knowledge in bone metabolism, bone disease and related skeletal disorders.

Therefore the course is best suited to the following groups:

  • Senior (Year3+) Trainees in paediatric or adult endocrinology or relative specialities (genetics/ metabolic/orthopaedics)
  • Clinical fellows with an interest in bone disease
  • Postdoctoral clinical and translational researchers in fields related to bone metabolism or skeletal disorders
  • Senior Nurse Specialists or Advanced Allied Health Professionals with experience in managing bone disorders (with a minimum of 5 years of experience).

Numbers will be limited to 48 delegates in order to promote interaction and discussion both within and outside the lecture theatre. Participants will have the opportunity to learn from and interact with some of leading experts in the field.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

At Kyowa Kirin, patients are at the center of everything we do. We are a global specialty pharmaceutical company dedicated to discovering and advancing innovative medicines for rare and hard-to-treat diseases where unmet need is greatest. Based in Japan with worldwide operations, we work across the continuum—from drug discovery to commercialization—guided by our commitment to patients and their families. Backed by more than 70 years of life sciences leadership, we focus on bone and mineral disorders, hemato-oncology, and rare diseases. Rooted in collaboration, we accelerate development through partnerships with industry, academia, patients, and healthcare providers. Learn more: KyowaKirin.com

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE
BridgeBio Logo

At BridgeBio, our mission is to turn beautiful science into meaningful medicines for the people who need it most. BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE